Diphenylhydantoin-induced hypogammaglobulinemia in a patient infected with human immunodeficiency virus.
A case is reported of reversible panhypogammaglobulinemia in a human immunodeficiency virus (HIV)-infected patient. Onset and resolution were temporally correlated with initiation and termination, respectively, of diphenylhydantoin therapy for a possible seizure. A rapid alteration in peripheral T-cell subpopulations was also noted in association with diphenylhydantoin administration. This case is compared with previous reports of diphenylhydantoin-associated hypogammaglobulinemia in non-HIV-infected patients. In addition, the case is discussed with regard to possible deleterious effects associated with the use of diphenylhydantoin as therapy for HIV-associated seizures or as an antiretroviral agent in HIV disease.
Britigan
B E
BE
Department of Internal Medicine, Veterans Administration Medical Center, Iowa City, Iowa.
D000328:Adult; D000361:Agammaglobulinemia / Q000139:chemically induced* / Q000150:complications / Q000503:physiopathology; D006679:HIV Seropositivity / Q000150:complications*; D006509:Hepatitis B / Q000150:complications; D006716:Homosexuality; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D010672:Phenytoin / Q000009:adverse effects*; D012640:Seizures / Q000150:complications / Q000188:drug therapy
D010672:Phenytoin